EUVIMEDEUVIMED entdecken
EditorialKommentarOpen Access

Pulmonary Arterial Hypertension Risk With BCR-ABL Tyrosine Kinase Inhibitors: Refining Risk With Nationwide Data

Jonah D Garry iD, Evan L Brittain iD

Circulation · 31.03.2026 · 153 (13) · 980-982

DOI: 10.1161/circulationaha.126.079012 ↗

Kurz gefasst

Editorial in der Zeitschrift Circulation, erschienen am 31.03.2026. Verfasst von Jonah D Garry und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: FDA HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

Editorialspulmonary arterial hypertensiontyrosine kinase inhibitors

Autor:innen und Institutionen

  • Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN.

ORCID-Profile: Jonah D Garry, Evan L Brittain

Förderung

  • FDA HHS
  • NHLBI NIH HHS

Zitieren

APA

Garry, J. D., & Brittain, E. L. (2026). Pulmonary Arterial Hypertension Risk With BCR-ABL Tyrosine Kinase Inhibitors: Refining Risk With Nationwide Data. Circulation, 153(13), 980-982. https://doi.org/10.1161/circulationaha.126.079012

Vancouver

Garry JD, Brittain EL. Pulmonary Arterial Hypertension Risk With BCR-ABL Tyrosine Kinase Inhibitors: Refining Risk With Nationwide Data. Circulation. 2026;153(13):980-982. doi:10.1161/circulationaha.126.079012

BibTeX
@article{Garry2026,
  author = {Garry, Jonah D and Brittain, Evan L},
  title = {Pulmonary Arterial Hypertension Risk With BCR-ABL Tyrosine Kinase Inhibitors: Refining Risk With Nationwide Data},
  journal = {Circulation},
  year = {2026},
  volume = {153},
  number = {13},
  pages = {980--982},
  doi = {10.1161/circulationaha.126.079012}
}
Kostenlos starten →